International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

International Dermatology Outcome Measures (IDEOM) : Report from the 2020 Annual Meeting. / Kohn, Alison H.; Alavi, Afsaneh; Armstrong, April W.; Babalola, Folawiyo; Garg, Amit; Gottlieb, Alice B.; Grilli, Lesley; Jemec, Gregor Borut Ernst; Latella, John; Marcus, Kendall; Merola, Joseph F.; Ortega-Loayza, Alex G.; Siegel, Daniel M.; Strand, Vibeke; Tan, Jerry K.L.; Perez-Chada, Lourdes M.

I: Dermatology, Bind 238, 2022, s. 430–437.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Kohn, AH, Alavi, A, Armstrong, AW, Babalola, F, Garg, A, Gottlieb, AB, Grilli, L, Jemec, GBE, Latella, J, Marcus, K, Merola, JF, Ortega-Loayza, AG, Siegel, DM, Strand, V, Tan, JKL & Perez-Chada, LM 2022, 'International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting', Dermatology, bind 238, s. 430–437. https://doi.org/10.1159/000518966

APA

Kohn, A. H., Alavi, A., Armstrong, A. W., Babalola, F., Garg, A., Gottlieb, A. B., Grilli, L., Jemec, G. B. E., Latella, J., Marcus, K., Merola, J. F., Ortega-Loayza, A. G., Siegel, D. M., Strand, V., Tan, J. K. L., & Perez-Chada, L. M. (2022). International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 238, 430–437. https://doi.org/10.1159/000518966

Vancouver

Kohn AH, Alavi A, Armstrong AW, Babalola F, Garg A, Gottlieb AB o.a. International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology. 2022;238:430–437. https://doi.org/10.1159/000518966

Author

Kohn, Alison H. ; Alavi, Afsaneh ; Armstrong, April W. ; Babalola, Folawiyo ; Garg, Amit ; Gottlieb, Alice B. ; Grilli, Lesley ; Jemec, Gregor Borut Ernst ; Latella, John ; Marcus, Kendall ; Merola, Joseph F. ; Ortega-Loayza, Alex G. ; Siegel, Daniel M. ; Strand, Vibeke ; Tan, Jerry K.L. ; Perez-Chada, Lourdes M. / International Dermatology Outcome Measures (IDEOM) : Report from the 2020 Annual Meeting. I: Dermatology. 2022 ; Bind 238. s. 430–437.

Bibtex

@article{ecc593c472d64005ad830dff0aedac4f,
title = "International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting",
abstract = "Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting. ",
author = "Kohn, {Alison H.} and Afsaneh Alavi and Armstrong, {April W.} and Folawiyo Babalola and Amit Garg and Gottlieb, {Alice B.} and Lesley Grilli and Jemec, {Gregor Borut Ernst} and John Latella and Kendall Marcus and Merola, {Joseph F.} and Ortega-Loayza, {Alex G.} and Siegel, {Daniel M.} and Vibeke Strand and Tan, {Jerry K.L.} and Perez-Chada, {Lourdes M.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",
year = "2022",
doi = "10.1159/000518966",
language = "English",
volume = "238",
pages = "430–437",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S Karger AG",

}

RIS

TY - JOUR

T1 - International Dermatology Outcome Measures (IDEOM)

T2 - Report from the 2020 Annual Meeting

AU - Kohn, Alison H.

AU - Alavi, Afsaneh

AU - Armstrong, April W.

AU - Babalola, Folawiyo

AU - Garg, Amit

AU - Gottlieb, Alice B.

AU - Grilli, Lesley

AU - Jemec, Gregor Borut Ernst

AU - Latella, John

AU - Marcus, Kendall

AU - Merola, Joseph F.

AU - Ortega-Loayza, Alex G.

AU - Siegel, Daniel M.

AU - Strand, Vibeke

AU - Tan, Jerry K.L.

AU - Perez-Chada, Lourdes M.

N1 - Publisher Copyright: © 2021 The Author(s).

PY - 2022

Y1 - 2022

N2 - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

AB - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

U2 - 10.1159/000518966

DO - 10.1159/000518966

M3 - Review

C2 - 34537770

AN - SCOPUS:85115977492

VL - 238

SP - 430

EP - 437

JO - Dermatology

JF - Dermatology

SN - 1018-8665

ER -

ID: 305409891